Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advances in the systemic treatment of therapeutic approaches in biliary tract cancer.
Mirallas O, López-Valbuena D, García-Illescas D, Fabregat-Franco C, Verdaguer H, Tabernero J, Macarulla T. Mirallas O, et al. Among authors: fabregat franco c. ESMO Open. 2022 Jun;7(3):100503. doi: 10.1016/j.esmoop.2022.100503. Epub 2022 Jun 10. ESMO Open. 2022. PMID: 35696747 Free PMC article. Review.
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters.
Rimini M, Loi E, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, Raposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Zavattari P, Casadei-Gardini A. Rimini M, et al. Among authors: fabregat franco c. Eur J Cancer. 2022 Nov;175:299-310. doi: 10.1016/j.ejca.2022.08.026. Epub 2022 Sep 28. Eur J Cancer. 2022. PMID: 36182816
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.
Rimini M, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: fabregat franco c. Sci Rep. 2022 Nov 5;12(1):18775. doi: 10.1038/s41598-022-22543-z. Sci Rep. 2022. PMID: 36335135 Free PMC article.
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.
Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, Vila-Casadesús M, Turpin A, Neuzillet C, Frigola J, Querol J, Yáñez-Bartolomé M, Castet F, Fabregat-Franco C, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernadó-Morales C, Haro N, Giles FJ, Pozo ÓJ, Miquel JM, Nuciforo PG, Vivancos A, Melé M, Serra V, Arribas J, Tabernero J, Peiró S, Macarulla T, Tian TV. Serra-Camprubí Q, et al. Among authors: fabregat franco c. Clin Cancer Res. 2023 Jan 17;29(2):432-445. doi: 10.1158/1078-0432.CCR-22-2551. Clin Cancer Res. 2023. PMID: 36374558 Free PMC article.
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
Rimini M, Fabregat-Franco C, Persano M, Burgio V, Bergamo F, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: fabregat franco c. Target Oncol. 2023 Jan;18(1):139-145. doi: 10.1007/s11523-022-00933-7. Epub 2023 Jan 23. Target Oncol. 2023. PMID: 36689074
Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases.
Fabregat-Franco C, Stradella A, Navarro V, Linares J, Galdeano M, Recalde S, Velasco R, Simo M, Fernadez A, Venthecourt AC, Falo C, Vazquez S, Bergamino M, Villanueva R, Pernas S, Gil-Gil MJ. Fabregat-Franco C, et al. Clin Transl Oncol. 2021 Sep;23(9):1761-1768. doi: 10.1007/s12094-021-02577-x. Epub 2021 Mar 11. Clin Transl Oncol. 2021. PMID: 33704689
Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models.
Yáñez-Bartolomé M, Serra-Camprubí Q, Arenas EJ, Escorihuela M, Castet F, Fabregat-Franco C, Querol J, Arribas J, Peiró S, Macarulla T, Tian TV. Yáñez-Bartolomé M, et al. Among authors: fabregat franco c. Methods Mol Biol. 2024;2806:139-151. doi: 10.1007/978-1-0716-3858-3_11. Methods Mol Biol. 2024. PMID: 38676801
Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
Fonseca E, Cabrera-Maqueda JM, Ruiz-García R, Naranjo L, Diaz-Pedroche C, Velasco R, Macias-Gómez A, Milisenda JC, Muñoz-Farjas E, Pascual-Goñi E, Gállego Perez-Larraya J, Saiz A, Dalmau J, Blanco Y, Graus F, Martinez-Hernandez E; Neuro-ICI-Spain study group. Fonseca E, et al. Lancet Neurol. 2023 Dec;22(12):1150-1159. doi: 10.1016/S1474-4422(23)00335-6. Lancet Neurol. 2023. PMID: 37977714 Review.
Clinical and genomic characterisation of early-onset pancreatic cancer.
Castet F, Fabregat-Franco C, Castillo G, Navarro V, Sierra A, Acosta DA, López-Valbuena D, Dienstmann R, Tabernero J, Vivancos A, Tian TV, Macarulla T. Castet F, et al. Among authors: fabregat franco c. Eur J Cancer. 2023 Nov;194:113338. doi: 10.1016/j.ejca.2023.113338. Epub 2023 Sep 9. Eur J Cancer. 2023. PMID: 37793216